The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

Plant biotechnology uses tools like genetic modification and bioengineering to enhance crops’ resilience, nutritional value, and sustainability in the face of challenges like climate change. Biosafety ...

Researchers have developed a machine learning model that predicts Cas9 proteins that can be tailored with designer properties for therapeutic use.

Zhang et al. present important findings that reveal a new role for TET2 in controlling glucose production in the liver, showing that both fasting and a high-fat diet increase TET2 levels, while its ...

CRISPR–Cas, a bacterial defence system that recognizes and slashes specific sequences in viral genomes, gave scientists the power to delete or edit genes with remarkable precision. Developed in ...

The cap would apply to plan participants up to age 26. A plan could apply to "selected insulin products." Products available with the $35 monthly cap would have to include at least one of each ...

including those affecting the Medicare Drug Price Negotiation Program and cost-sharing requirements for vaccines and insulin products. 10. Zero cost-sharing for adult vaccines: Effective for plan ...

Notably, it finalized provisions determining that the deductible for seniors with Medicare prescription drug plans doesn’t apply to covered insulin products and that seniors’ cost-sharing for ...

CRISPR/Cas9 technology has revolutionized genetic and biomedical research in recent years. It enables editing and modulation of gene function with an unparalleled precision and effectiveness. Among ...

Insulin products covered under Medicare Part D will also be subject to caps, with out-of-pocket costs limited to a maximum of $35 per month per covered insulin product. Additionally, CMS finalized ...

Insulin biosimilars are near-identical versions of branded insulin products, developed to provide the same safety, efficacy and quality at a lower cost. Unlike generic drugs, which are chemically ...